A FASTer FDA?

A new bill recently debated in the US Congress seeks to streamline the approval process for drugs.

By | March 19, 2012

WIKIMEDIA COMMONS, TIBOR KADEK

The Faster Access to Specialized Treatments (FAST) Act made its debut on the floor of the US House of Representatives earlier this month. The bill is seeking to extend fast-tracked drug approvals beyond HIV/AIDS and cancer drugs, which already benefit from legislation that have increased investment, shortened timeframes, and decreased burdens of proof for garnering US Food and Drug Administration approval.

The FDA is cautioning patience because in order to accelerate the approval of drugs that treat Parkinson's, Alzheimer's, diabetes, and other diseases, scientifically meaningful clinical endpoints must first be established to ensure that the right safety and efficacy data is be submitted and evaluated. "We agree with the sentiment behind [the FAST Act] but have to avoid inadvertently lowering the efficacy standard," said director of the FDA's Center for Drug Evaluation and Research Janet Woodcock at a Congressional subcommittee hearing on last Thursday (March 8).

But John Maraganore, CEO of Alnylam Pharmaceuticals, told the same subcommittee that the benefits of the FAST Act could be great when those endpoints are agreed upon and can consistently be measured to demonstrate a reasonable likelihood of clinical benefit. "If the accelerated approval pathway is modernized, and that is reduced to actual practice so people can see it, you can logically expect investors to feel more bullish about investing in biotech," Maraganore told BioCentury. "As a result, I would expect more investment in breakthrough medicines, and more medicines coming into the pipeline that would take advantage of the accelerated or traditional pathways."

The FAST Act will be further debated by the House of Representatives, and the ideas it contains could be absorbed into the Prescription Drug User Fee Act (PDUFA) V, which expires in September and is expected to be reauthorized.

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech